Themis Medicare Ltd
Themis Medicare Q1 FY25 earnings call: Revenue & Margins
Q1 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹123Cr
- +27.3% YoY
- Net profit
- ₹25Cr
- +35.7% YoY
- Margin
- 23.73%
- +1.2 pp YoY
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Themis Medicare Ltd's Q1 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1 FY25 Net Revenue: Rs. 122.99 Cr, up 27.26% YoY from Rs. 96.65 Cr in Q1 FY24 (Page 8). Q1 FY25 EBITDA: Rs. 29.18 Cr, up 34.19% YoY (Q1 FY24: Rs. 21.74 Cr).
From Themis Medicare Ltd's Q1 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1 FY25 Net Revenue: Rs. 122.99 Cr, up 27.26% YoY from Rs. 96.65 Cr in Q1 FY24 (Page 8).
- Formulation Segment grew ~53% YoY in Q1 FY25 (Page 8).
- Hospital Business grew over 9% YoY; Trade and Co-marketing businesses grew over 41% and 37% YoY respectively in Q1 FY25 (Page 8).
- EBITDA for Q1 FY25: Rs. 29.18 Cr, up 34.19% YoY; PAT: Rs. 24.68 Cr, up 35.69% YoY (Page 8).
- Management outlook: Company expects sustained growth in Trade and Hospital businesses, focusing on capacity building and new product launches, especially in Critical and Intensive Care divisions (Page 6).
2 more points from Themis Medicare Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Themis Medicare Ltd said on order book & pipeline — free account, 30 seconds.
Themis Medicare Ltd — Quarterly revenue & net profit
Themis Medicare Ltd Q1 FY25 results — key figures
| ₹ Cr | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue | 123 | 97 | +27.3% | 98 | +25.7% |
| Operating profit (EBITDA) | 29 | 22 | +34.2% | 9 | +214.1% |
| Operating margin | 23.73% | 22.49% | +1.2 pp | 9.5% | +14.2 pp |
| Profit before tax | 31 | 23 | +39.2% | 9 | +258.6% |
| Net profit (PAT) | 25 | 18 | +35.7% | 7 | +271.7% |
| EPS (₹) | 2.68 | 1.98 | +35.4% | 0.72 | +272.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹77 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Themis Medicare's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q1 FY25)
1,746 Cr, a 9% increase YoY. Key concall takeaways from Jubilant Pharmova Ltd's Q1 FY25 earnings call — and how it ranks against sector peers.
- NGL Fine Chem (Q1 FY25)
Q1 FY25 revenue from operations: ₹90.75 crores, up 27.75% year-on-year (YoY) from ₹71.04 crores in Q1 FY24 (Page 8). Key concall takeaways from NGL Fine Chem…
- Shree Ganesh Rem (Q1 FY25)
Q1FY25 Revenue from Operations: ₹24.78 crore, down 8% YoY from Q1FY24's ₹26.84 crore. Key concall takeaways from Shree Ganesh Remedies Ltd's Q1 FY25 earnings…
- Fermenta Biotech (Q1 FY25)
Q1-FY25 consolidated operational revenue: INR 781 million, down 5.3% YoY (Q1-FY24: INR 824 million). Key concall takeaways from Fermenta Biotech Ltd's Q1 FY25…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Themis Medicare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Themis Medicare Ltd Q1 FY25 results?
Q1 FY25 Net Revenue: Rs. 122.99 Cr, up 27.26% YoY from Rs. 96.65 Cr in Q1 FY24 (Page 8). Q1 FY25 EBITDA: Rs. 29.18 Cr, up 34.19% YoY (Q1 FY24: Rs. 21.74 Cr).
What is Themis Medicare Ltd share price analysis?
Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.